(CercleFinance.com) – Bayer will present key data across its entire oncology portfolio, illustrating significant advances in cancer treatment, at the ASCO Annual Meeting in 2022.
For prostate cancer, the group will present research data from NUBEQA (darolutamide) on non-metastatic castration-resistant prostate cancer (nmCRPC) and metastatic hormone-sensitive prostate cancer (mHSPC), and the research of Xofigo (radium Ra 223 dichloride) in metastatic castration-resistant prostate cancer (mCRPC)
Presentations for Vitrakvi (larotrectinib) include long-term efficacy and safety data in patients with TRK fusion cancer from integrated and expanded analyses, quality of life update health-related TRK fusion cancer patients and sub-analyzes for TRK fusion cancer patients with primary central nervous system (CNS) tumors and lung cancer.
Other presentations will focus on investigator-initiated research (IIR) for Stivarga (regorafenib) and Nexavar (sorafenib) in several areas of oncology.
Copyright © 2022 CercleFinance.com. All rights reserved.
Did you like this article ? Share it with your friends with the buttons below.
